Printer Friendly

IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER

 IMMUNOGEN EXPANDS MANAGEMENT TEAM:
 DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
 CAMBRIDGE, Mass., July 14 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of Donald J. McCarren as president and as chief operating officer, a newly created position. McCarren was most recently president of Adria Laboratories, the developer and marketer of Adriamycin, one of the world's leading cancer chemotherapeutics. McCarren also becomes a member of ImmunoGen's board of directors. Mitchel Sayare continues as chairman of the board and chief executive officer.
 "Don McCarren has directed a major franchise in cancer therapeutics -- including product development and marketing," noted chairman and CEO Sayare. "His proven leadership in critical operating and management functions -- development, clinical testing, marketing and sales -- will enhance our efforts to bring our products to the market expeditiously."
 Sayare pointed out that "McCarren's presence is particularly valuable at this stage in the company's growth: It coincides with the initiation of pivotal clinical studies with our lead product, Oncolysin(R) B, for the treatment of lymphomas and leukemias, the rapid development of our pipeline of Oncolysin products, the expansion of manufacturing in anticipation of full commercial sales and the application of next-generation technologies to the development of new immunoconjugates for the treatment of cancer and other diseases."
 McCarren, 52, has almost 30 years of pharmaceutical experience. He joined Adria as president in 1990, where he had direct responsibility for North American operations, overseeing product sales in excess of $100 million. From 1984 until 1989, he was with Adria's parent, the multinational pharmaceutical company, Erbamont, as vice president, business development and vice president of Far East and Australasian operations. During that time, he helped define the company's corporate strategies and established Erbamont's strategic push into the Far East -- particularly Japan. In 1989, he was named corporate vice president of worldwide marketing and business development for Erbamont, overseeing its worldwide oncology and non-oncology pharmaceutical businesses. From 1971-1984, McCarren held various positions with Abbott Labs, Pfizer and Merck. He holds a B.A. from Hofstra University, an M.B.A. from Fairleigh Dickinson and a Ph.D. in developmental economics from the University of Miami.
 ImmunoGen, Inc. is a Cambridge-based biotechnology company that develops biopharmaceuticals, primarily for the treatment of cancer. The company produces proprietary toxins, drugs and biologicals conjugated to highly specific monoclonal antibodies which search out and destroy cancer cells. ImmunoGen currently has three products in human clinical trials in the United States, Canada and Europe, and has filed with the U.S. Food and Drug Administration to begin human testing of its fourth product.
 -0- 7/14/92
 /CONTACT: Mark Ratner, director of external communications for ImmunoGen, 617-661-9312/
 (IMGN) CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER


CN -- NE001 -- 8934 07/14/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:459
Previous Article:FIRST DELAWARE LIFE INSURANCE COMPANY MOVES HEADQUARTERS TO DELAWARE
Next Article:DESIGN ACOUSTICS EARNS DESIGN AND ENGINEERING AWARD FOR NEW SPEAKER
Topics:


Related Articles
ELAN NAMES GEANEY PRESIDENT AND CREATES OFFICE OF CHAIRMAN
IMMUNOGEN, INC. NAMES DIXIE ESSELTINE, M.D., DIRECTOR OF ONCOLOGY
IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT
IMMUNOGEN, INC. NAMES JOHN A. KNOX DIRECTOR OF HUMAN RESOURCES
IMMUNOGEN, INC. NAMES ROBERT J. CONNAUGHTON, JR., GENERAL COUNSEL
IMMUNOGEN, INC. NAMES CAROL A. GLOFF VICE PRESIDENT OF REGULATORY AFFAIRS
IMMUNOGEN ANNOUNCES RESIGNATION OF PRESIDENT DONALD J. McCARREN
IMMUNOGEN PROMOTES DIXIE ESSELTINE, M.D., TO VICE PRESIDENT, MEDICAL AFFAIRS
I-FLOW CORPORATION ANNOUNCES ELECTION OF JAMES DAL PORTO TO BOARD, PROMOTION OF GAYLE ARNOLD TO TREASURER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters